Chugai to sell C&C Research Laboratories stake to JW Pharmaceutical
Category: #health  By Mateen Dalal  Date: 2019-11-29
  • share
  • Twitter
  • Facebook
  • LinkedIn

Chugai to sell C&C Research Laboratories stake to JW Pharmaceutical

Japan’s research-based pharma company, Chugai Pharmaceutical Co., Ltd. has recently made it to headlines when it agreed to change the equity structure of C&C Research Laboratories (C&C), a Korean joint venture which it formed with JW Pharmaceutical Corp.

According to reliable sources, Chugai would sell its C&C’s share to JWP by the end of this year. This would make C&C a fully owned subsidiary of JWP and would allow it to continue its research in drug discovery with independent management.

Reportedly, the move comes after both the firms agree that C&C has flourished to advance its drug candidates such as gout treatment and atopic dermatitis, and is quite capable of organizing its research programs as an independent entity. Both Chugai and JWP will maintain cordial partnerships and favorably collaborate on C&C’s latest drug candidates.

Speaking on the move, Tatsuro Kosaka, President and CEO, Chugai, said that C&C has developed numerous drug candidates which have entered the clinical study stage. The company has also attained the initial goal of creating a novel drug discovery base with superior technological abilities in Korea.

Kosaka added that Chugai values JWP’s partnership and is looking forward to seeing several ground-breaking innovations from C&C in the forthcoming years.

As per Young sub Shin, CEO, JWP, C&C has developed synergy by integrating Korea’s human infrastructure with Chugai’s knowledge on latest drug development. The company is thankful for Chugai’s continuous support ever since its inception and will work hard on growing C&C as an international R&D venture.

Prior to this news, Chugai had revealed that its “Annual Report 2018” had bagged an award in the 7th WICI Japan Award for Excellence in Integrated Reporting. Reportedly, this is the first award that the company has received from WICI Japan, which was for “the Prize for Excellence in Integrated Reporting”.

Sources cite that Chugai’s annual report was acclaimed as an outstanding example of integrated reporting with a superior level of thoroughness that grants an insightful view of the firm’s future.

Source Credit: https://www.chugai-pharm.co.jp/english/news/detail/20191127160000_672.html

  • share
  • Twitter
  • Facebook
  • LinkedIn


About Author

Mateen Dalal    

Mateen Dalal

Mateen has completed his Bachelor’s degree in electronics and telecommunication engineering, post which he lent his proficiency to the industry, working as a quality and test engineer. Drawn intricately toward the field of content creation however, Mateen soon switc...

Read More

More News By Mateen Dalal

Sensorium registers new branch in UAE to expand global presence
Sensorium registers new branch in UAE to expand global presence
By Mateen Dalal

Sensorium, developer of the Sensorium Galaxy metaverse, has registered its new branch in the United Arab Emirates (UAE) as Dubai gradually becomes a global hub for metaverse companies. The new entity, slated to be officially inaugurated in the com...

Saepio, Echoworx partner to deliver Next-Gen security solutions
Saepio, Echoworx partner to deliver Next-Gen security solutions
By Mateen Dalal

Saepio Information Security, a market leader in statement encryption and cloud-based email, has reportedly announced its collaboration with Echoworx to offer next-generation safe delivery of sensitive and secret information to any email receiver...

Ather Energy raises $250 million to stay ahead in competition
Ather Energy raises $250 million to stay ahead in competition
By Mateen Dalal

Electric scooter producer Ather Energy has reportedly secured $250 million in a new funding round. As per reports, the investment round is in its early stages. The company’s goal is to obtain $200 million to $250 million to compete in the EV...